Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
PHLDA1 Monoclonal Antibody (OTI4G2), TrueMAB™, OriGene

Mouse Monoclonal Antibody
Supplier: OriGene TA810938

Description
Cytotoxic T lymphocyte (CTL)-mediated cytotoxicity constitutes an important component of specific effector mechanisms in immunosurveillance against virus-infected or -transformed cells. Two mechanisms appear to account for this activity, one of which is the perforin-based process. Independently, a FAS-based mechanism involves the transducing molecule FAS (APO-1) and its ligand (FAS-L). The human FAS (APO-1) protein is a 48 kDa cell surface glycoprotein that belongs to a family of receptors that includes CD40, nerve growth factor receptors and tumor necrosis factor receptors. The FAS antigen is expressed on a broad range of lymphoid cell lines, and is expressed at high levels in T cells subsequent to crosslinking of the T cell receptor (TCR). A previously undescribed protein, TDAG51, restores activation- induced apoptosis in cells that have lost the ability to display Fas in response to activation.Specifications
PHLDA1 | |
Monoclonal | |
1 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
Q8WV24 | |
PHLDA1 | |
Human recombit protein fragment corresponding to amino acids 183-401 of human PHLDA1 produced in E.coli. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
Western Blot | |
OTI4G2 | |
Unconjugated | |
PHLDA1 | |
DT1P1B11, PHRIP, TDAG51 | |
Mouse | |
Affinity Chromatography | |
RUO | |
22822 | |
-20° C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction